Pharmaceuticals News and Research

RSS

Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.

18 Oct 2011

vRad announces premier radiology partnership with ICON

Virtual Radiologic (vRad), a technology-enabled national radiology practice, has announced a premier radiology partnership with ICON Medical Imaging (ICON), the medical imaging division of ICON plc.

18 Oct 2011

Roche to acquire Anadys Pharmaceuticals

Anadys Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement to be acquired by Roche.

18 Oct 2011

National award encourages bio-science student researchers

A key challenge for the bio-sciences sector is to keep its best research graduates in science and in Australia. The national student awards recognise and encourage promising research students and raise awareness of biosciences research translation and applications.

17 Oct 2011

Gut bacteria shown to affect statin efficacy in some people

The team led by a Duke University scientist has identified three bile acids produced by gut bacteria that were evident in people who responded well to a common cholesterol-lowering drug called simvastatin. The finding, published Oct. 13, 2011, in PLoS One, demonstrates how gut bacteria can cause inherent differences in the way people digest, metabolize and benefit from substances such as drugs.

17 Oct 2011

Johns Hopkins Brain Science Institute organizes Drug Discovery in Academia symposium

A symposium to be hosted by the Johns Hopkins Brain Science Institute (BSi) on Oct. 18 at the Baltimore Convention Center will bring together the pharmaceutical industry and academic-based research institutions with the common goal of exploring how the two can best work together to enhance and facilitate the discovery of new drugs.

15 Oct 2011

Watson confirms patent challenge of generic Daytrana

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Methylphenidate Transdermal System, 10 mg/9 hrs, 15 mg/9 hrs, 20 mg/9 hrs, and 30 mg/9 hrs.

15 Oct 2011

Teva acquires Cephalon

Teva Pharmaceutical Industries Ltd. announced today that it has completed its acquisition of Cephalon, Inc. The combined company will have a significant presence in over 60 countries and generated approximately $20 billion in revenues on a pro-forma basis for the twelve months ended June 2011.

15 Oct 2011

Janssen, BeiGene enter in-licensing agreement for two clinical-stage oncology compounds

BeiGene, Ltd., today announced that it has entered into exclusive in-licensing and co-development agreements with Janssen Pharmaceutica NV and its affiliates for two clinical-stage oncology compounds.

15 Oct 2011

Barcodes evolving into a broader class of identifiers in new ways

What if you could trace the history of everything you buy back to its origins? Using your smart phone camera, you could learn what factory made the ingredients in your heart medication, what country grew the corn in your breakfast cereal, or even how to recycle the phone. You could follow the whole life cycle of a product and everyone who handled it along the way to ensure that the medicine you're taking isn't counterfeit and the food you're eating is safe.

14 Oct 2011

Researchers identify gut bacteria bile acids linked to effectiveness of statin drugs in lowering cholesterol

Statins can be effective at lowering cholesterol, but they have a perplexing tendency to work for some people and not others. Gut bacteria may be the reason.

14 Oct 2011

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Four companies are to develop broad-spectrum therapeutics-antibiotics, antivirals and an antitoxin-to prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

14 Oct 2011

EMKinetics initiates TranStim therapy pivotal trial for urge incontinence, overactive bladder

EMKinetics, Inc. announced today initiation of the TranStim Transdermal Neuromodulation System pivotal trial for patients suffering from urge incontinence and overactive bladder.

14 Oct 2011

Scientists conclude pesticide contamination as a major problem in Europe

Pesticides are a bigger problem than had long been assumed. This is the conclusion of a study in which scientists analysed data on 500 organic substances in the basins of four major European rivers. It was revealed that 38 per cent of these chemicals are present in concentrations which could potentially have an effect on organisms.

14 Oct 2011

Positive data from Anadys' setrobuvir Phase IIb combination study on genotype 1 HCV

Anadys Pharmaceuticals, Inc. today released interim antiviral response and safety data from an ongoing Phase IIb study of setrobuvir in combination with pegylated interferon and ribavirin (P/R) in genotype 1 hepatitis C patients.

14 Oct 2011

Entirely new platform to assist in developing antimalarial drugs

Malaria has been one of the world's biggest killers for as long as records have been kept. With resistance to existing antimalarial drugs on the rise, there is a renewed push to find different ways to fight it. Two University of Houston (UH) engineers have stepped up to the plate to answer the call.

14 Oct 2011

Oncobiologics signs two major pharmaceutical agreements

Oncobiologics announced today that it has signed two major agreements. The first is with Parilis Biopharmaceuticals, an early-stage biotech company, and involves worldwide licensing for an undisclosed biotherapeutic product. The second is with a US based large pharmaceutical company to conduct research focused on solving issues related to downstream processing of monoclonal antibodies.

14 Oct 2011

Cylene advances preclinical development of CX-5461 for treatment of cancer

Cylene Pharmaceuticals, Inc. has advanced its targeted, non-genotoxic, activator of p53 for the treatment of leukemias, lymphomas and multiple myeloma through formal preclinical development, the Company announced today.

14 Oct 2011

Noven claims patent infringement over Daytrana, files lawsuit against Watson

Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court of New Jersey against Watson Pharmaceuticals for infringement of certain Noven patents by Watson.

14 Oct 2011

WuXi PharmaTech announces acquisition of Abgent

WuXi PharmaTech Inc., a leading pharmaceutical, biotechnology and medical device research and development services company with operations in China and the United States, today announced the acquisition of Abgent, Inc., a provider of biological research reagent products and services based in Suzhou, China, and San Diego, California.

14 Oct 2011